Antisense IAP nucleobase oligomers and uses thereof
AssigneeAegera Therapeutics, Inc.
InventorsEric LaCasse, Daniel McManus, Jonathan P. Durkin
Life of this patent
Estimating the term…
Abstract
The present invention features nucleobase oligomers that hybridize to IAP polynucleotides, and methods for using them to enhance apoptosis and treat proliferative diseases.
Claims41
A substantially pure nucleobase oligomer of up to 30 nucleobases in length, said nucleobase oligomer comprising at least eight consecutive nucleobases of a sequence selected from the group consisting of SEQ ID NOs:
- 97, 98, 99, 143, 147, 151, 287, 289, and 300-460.
A pharmaceutical composition comprising (i) a nucleobase oligomer of up to 30 nucleobases in length, said nucleobase oligomer comprising at least eight consecutive nucleobases of a sequence selected from the group consisting of SEQ ID NOs:
- 97, 98, 99, 143, 147, 151, 287, 289, and 300-460;
- and (ii) a pharmaceutically acceptable carrier.
A catalytic RNA molecule capable of cleaving XIAP, HIAP1, or HIAP2 mRNA.
An expression vector comprising a nucleic acid encoding a catalytic RNA molecule, the binding arms of which contain at least eight consecutive nucleobases corresponding to a sequence of any one of Tables 1, 2, 6, and 7, said nucleic acid positioned for expression in a mammalian cell.
A double-stranded RNA molecule comprising between 21 and 29 nucleobases, said RNA molecule comprising at least eight consecutive nucleobases corresponding to a sequence of any one of Tables 1, 2, 6, and 7.
A double-stranded RNA molecule comprising between 50 and 70 nucleobases, said RNA molecule comprising a first domain of between 21 and 29 nucleobases that comprise least eight consecutive nucleobases corresponding to a sequence of any one of Tables 1, 2, 6, and 7;
- a second domain complementary to said first domain, and a loop domain situated between said first and said second domains.
An expression vector comprising a nucleic acid molecule encoding a double stranded RNA molecule comprising between 50 and 70 nucleobases, said RNA molecule comprising a first domain of between 21 and 29 nucleobases that comprise least eight consecutive nucleobases corresponding to a sequence of any one of Tables 1, 2, 6, and 7;
- a second domain complementary to said first domain, and a loop domain situated between said first and said second domains, said nucleic acid positioned for expression in a mammalian cell.
An oligonucleotide consisting of a sequence selected from SEQ ID NOs:
- 97, 98, 99, 143, 147, 151, 287, 289, and 300-460.
Dependencies are inferred from the claim text.